These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Early removal of the Norplant System. Mayeaux EJ; Maddox SA; Baudoin M J Am Board Fam Pract; 1996; 9(3):215-9. PubMed ID: 8743236 [No Abstract] [Full Text] [Related]
26. Emergency contraception is not associated with reduction in contraceptive use or an increase in adverse health outcomes. Murphy PA J Midwifery Womens Health; 2004; 49(3):266-7. PubMed ID: 15134683 [No Abstract] [Full Text] [Related]
27. Comparative risks of venous thromboembolism among users of oral contraceptives containing drospirenone and levonorgestrel. Heinemann K; Heinemann LA J Fam Plann Reprod Health Care; 2011 Jul; 37(3):132-5. PubMed ID: 21659330 [No Abstract] [Full Text] [Related]
28. Hyperglycaemic episodes in a young woman after taking levonorgestrel-containing oral contraceptives. Rennie NJ N Z Med J; 1994 Oct; 107(988):440-1. PubMed ID: 7970351 [No Abstract] [Full Text] [Related]
29. [Evaluation of the pre-introduction of contraception by means of subcutaneous levonorgestrel implants in Burkina Faso]. Lankoande J; Ouedraogo A; Dao B; Ouedraogo CM; Bonane B; Toure B; Ouattara T; Kabore I; Millogo B; Kone B Dakar Med; 1998; 43(1):79-82. PubMed ID: 9827162 [TBL] [Abstract][Full Text] [Related]
30. Risk of venous thromboembolism among users of third generation oral contraceptives compared with users of oral contraceptives with levonorgestrel before and after 1995: cohort and case-control analysis. Jick H; Kaye JA; Vasilakis-Scaramozza C; Jick SS BMJ; 2000 Nov; 321(7270):1190-5. PubMed ID: 11073511 [TBL] [Abstract][Full Text] [Related]
31. [Changed routines in connection with first prescription of oral contraceptives. Lower risk of venous thromboembolism with levonorgestrel preparations]. Milsom I; Odlind V; von Schoultz B; Ostlund I; Persson E Lakartidningen; 2002 Jan; 99(1-2):10-2, 15. PubMed ID: 11871161 [No Abstract] [Full Text] [Related]
32. The risk of deep venous thrombosis associated with injectable depot-medroxyprogesterone acetate contraceptives or a levonorgestrel intrauterine device. van Hylckama Vlieg A; Helmerhorst FM; Rosendaal FR Arterioscler Thromb Vasc Biol; 2010 Nov; 30(11):2297-300. PubMed ID: 20798377 [TBL] [Abstract][Full Text] [Related]
33. Risk of nonfatal venous thromboembolism with oral contraceptives containing norgestimate or desogestrel compared with oral contraceptives containing levonorgestrel. Jick SS; Kaye JA; Russmann S; Jick H Contraception; 2006 Jun; 73(6):566-70. PubMed ID: 16730485 [TBL] [Abstract][Full Text] [Related]
35. Subdermal levonorgestrel implants. Three years' experience in Cairo, Egypt. Rizk DE J Reprod Med; 1995 Sep; 40(9):638-44. PubMed ID: 8576880 [TBL] [Abstract][Full Text] [Related]
36. Effect of Norplant contraceptive on the bones of Nigerian women as assessed by quantitative ultrasound and serum markers of bone turnover. Vanderjagt DJ; Sagay AS; Imade GE; Farmer SE; Glew RH Contraception; 2005 Sep; 72(3):212-6. PubMed ID: 16102558 [TBL] [Abstract][Full Text] [Related]
37. Endometrial vasculature in Norplant users: preliminary results from a hysteroscopic study. Hickey M; Fraser I; Dwarte D; Graham S Hum Reprod; 1996 Oct; 11 Suppl 2():35-44. PubMed ID: 8982744 [TBL] [Abstract][Full Text] [Related]
38. The Norplant experience in Zaria: a ten-year review. Haggai DN Afr J Reprod Health; 2003 Aug; 7(2):20-4. PubMed ID: 14677296 [TBL] [Abstract][Full Text] [Related]